The question
Bremelanotide, also known as PT-141, is the active ingredient in Vyleesi. Research-name record. The US approval concerns a particular prescription product and indication; it does not automatically cover any vial sold under the research name. Vyleesi is indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prescribing information.
The indication has boundaries
The label describes low desire causing marked distress or interpersonal difficulty, excluding cases due to another medical or psychiatric condition, relationship problems, or medication or drug effects. It does not indicate Vyleesi for men, postmenopausal women, or enhancement of sexual performance. Current manufacturer-hosted label, checked September 26, 2026.
These boundaries are important when a brief product description says only “for libido.” A reader needs to know which clinical problem was evaluated and whether it matches the question they are asking. A broader phrase can conceal meaningful differences between treatment of a defined disorder and a general enhancement claim.
What the pivotal trials measured
The two RECONNECT trials randomized 1,267 women and compared bremelanotide with placebo over 24 weeks. Both found improvement in the primary measures of sexual desire and distress related to low desire. However, the change in the number of satisfying sexual events, a key secondary endpoint, did not significantly differ between groups. Original phase 3 report.
That combination of findings is more informative than a single success label. Desire, distress and the number of events are different outcomes. A benefit in one measure should not be rewritten as a benefit in every related measure. Equally, the negative secondary comparison does not erase the positive primary findings.
The study report includes manufacturer affiliations and financial disclosures. Those disclosures belong in an evidence assessment, alongside design and results; they do not, by themselves, decide whether a finding is valid. Trial disclosures.
Approval includes safety limitations
The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease. It warns about temporary blood-pressure increases, reduced heart rate, and focal hyperpigmentation. Nausea occurred in 40% of treated participants in the phase 3 trials. These are selected points, not the full safety information. Prescribing information.
An approval therefore does not mean a medicine suits everyone. Its usefulness depends on the balance between a relevant potential benefit and the person's clinical circumstances, assessed with a qualified prescriber.
Why the name on another preparation is not enough
For a different preparation, ask for its own product identity and regulatory record. An ingredient name cannot establish manufacturing quality, formulation equivalence or a matching delivery system. Compounded drugs are not FDA-approved. FDA explanation.
Our peptide introduction explains the category. For another example of why specific products and study populations matter, see tirzepatide versus semaglutide.
Sources & further reading
Research context last reviewed September 26, 2026. Last updated October 6, 2026. Educational reading, not individual medical advice. How this article was prepared.
